MAYO CLINIC

Genomadix and Mayo Clinic collaborate on enhanced telestroke services in the U.S., leveraging FDA-cleared Genomadix Cube CYP2C19 System for rapid CYP2C19 genotyping to guide personalized dual-antiplatelet therapy decisions.

PDS Biotechnology Corporation's Q3 2024 10-Q filing shows R&D expenses up to $6.8M, G&A down to $3.4M, net loss at $10.7M, interest expenses at $547,964, and cash equivalents at $49.8M. The company focuses on Versamune® and PDS01ADC platforms, requires additional capital, and faces cash balance risks.

MyPhenome test predicts future weight gain, with participants having abnormal satiation and high gene risk scores experiencing 4% more weight gain over five years, emphasizing the need for early intervention in obesity.

Genascence's GNSC-001, a gene therapy for OA, received FDA Fast Track designation. GNSC-001 targets IL-1, a key mediator in OA pathogenesis, aiming for long-term inhibition with a single injection. Phase 1 data showed GNSC-001 was well-tolerated and improved pain and function scores.

Perspective Therapeutics reported Q3 2024 financial results, with $267.8 million in cash and investments, expected to fund operations into mid-2026. Key developments include advancing [212Pb]VMT01 trials in melanoma patients and [212Pb]VMT-α-NET in neuroendocrine tumors. The company started shipping from a second manufacturing facility in Somerset, New Jersey, and purchased additional facilities in Houston, Chicago, and Los Angeles. Q3 2024 showed a net loss of $15.1 million ($0.21 per share), with research and development expenses at $12.0 million and general administrative expenses at $7.0 million.

Perspective Therapeutics announced Q3 2024 financial results, highlighting progress in clinical programs for melanoma and neuroendocrine tumors, expansion of manufacturing facilities, and sufficient funding through mid-2026.

AI in healthcare is booming, with Mayo Clinic and Elon Musk's Grok AI leading the charge. Major tech companies like Nvidia, Google, and Microsoft showcased healthcare AI tools at the HLTH conference. Avant Technologies and Ainnova Tech formed a joint venture to advance early disease detection using AI, targeting a $67.4 billion market by 2027. Other companies like Recursion Pharmaceuticals, Exscientia, Absci Corporation, and Twist Bioscience are also making strides in AI-driven healthcare innovations.

Avant Technologies and Ainnova Tech form joint venture, Ai-nova Acquisition Corp, to commercialize Ainnova's VisionAI platform and retinal cameras for early disease detection, aiming to make retinal scanning a standard in primary care. The AI healthcare market is projected to grow significantly, with Avant and Ainnova targeting North America and Europe for commercialization.

The Lupus Foundation of America honors Dr. Brad H. Rovin with the 2024 Evelyn V. Hess Award for his research on lupus nephritis, and Dr. Alí Duarte-García with the 2024 Mary Betty Stevens Young Investigator Prize for his contributions to lupus research.